Engineered DNA-encoded PCSK9 inhibitors may provide an effective alternative for treating high cholesterol
Friday, November 16, 2018 - 14:20
in Health & Medicine
Researchers have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream. Results of preclinical studies showed a significant cholesterol decrease, opening the door for further development of this approach as a simple, less frequent and cost-effective therapy.